We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lichen-Derived Dye May Prevent Alzheimer’s by Neutralizing Toxic Peptides

By LabMedica International staff writers
Posted on 14 Dec 2011
A dye derived from lichens is among the candidate compounds being tested for their ability to convert toxic prefibrillar assemblies of amyloid-beta (A-beta) polypeptides – the cause of neuron death in Alzheimer’s disease – into mature, end-stage amyloid fibrils that are thought to be largely nontoxic.

The dye under consideration by investigators at the Max Delbruck Center for Molecular Medicine (Berlin, Germany) is called O4. This compound is a blue dye that was isolated from lichens together with the reddish-brown dye orcein.

The investigators reported in the November 20, 2011, issue of the journal Nature Chemical Biology that O4 directly bound to hydrophobic amino acid residues in A-beta peptides and stabilized the self-assembly of beta-sheet-rich protofibrils and fibrils. The O4-mediated acceleration of amyloid fibril formation efficiently decreased the concentration of small, toxic A-beta oligomers in complex, heterogeneous aggregation reactions.

O4 treatment suppressed inhibition of long-term potentiation by A-beta oligomers in hippocampal brain slices, results that support the hypothesis that small, diffusible prefibrillar amyloid species rather than mature fibrillar aggregates are toxic for mammalian cells.

“This is a new mechanism,” said senior author Dr. Erich Wanker, professor of neuroproteomics at the Max Delbruck Center for Molecular Medicine. “Up to now it has been considered to be very difficult to stop the formation of small toxic protein assemblies. If our hypothesis is correct that the small aggregates, which are precursors of plaques, indeed cause neuronal death, with O4 we would have a new mechanism to attack the disease. We hope that our findings will stimulate research activities in this direction, especially in drug discovery.”

Related Links:

Max Delbruck Center for Molecular Medicine


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Homocysteine Quality Control
Liquichek Homocysteine Control

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more